Incyte
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 2.5K
- Market Cap
- $12.6B
- Introduction
Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of proprietary therapeutics. It focuses on hematology and oncology, and inflammation and autoimmunity therapeutic areas. The company was founded in April 1991 and is headquartered in Wilmington, DE.
To Evaluate the Safety, and Pharmacokinetics of Parscaclisib in Participants With Normal Hepatic Function and Hepatic Impairment.
- First Posted Date
- 2021-04-05
- Last Posted Date
- 2022-08-26
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 21
- Registration Number
- NCT04831944
- Locations
- 🇺🇸
Orange County Research Center, Tustin, California, United States
🇺🇸Inland Empire Liver Foundation, Rialto, California, United States
🇺🇸Orlando Clinical Research Center, Orlando, Florida, United States
Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL Patients
- Conditions
- Diffuse Large B-cell Lymphoma
- Interventions
- First Posted Date
- 2021-04-01
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 899
- Registration Number
- NCT04824092
- Locations
- 🇨🇳
Morphsys Research Site, Taoyuan, Taiwan
🇬🇧MorphoSys Research Site, Wolverhampton, United Kingdom
🇷🇺Morphosys research site, UFA, Russian Federation
A Study to Evaluate the Efficacy and Safety of INCB054707 in Participants With Vitiligo
- First Posted Date
- 2021-03-26
- Last Posted Date
- 2024-04-11
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 171
- Registration Number
- NCT04818346
- Locations
- 🇺🇸
Investigative Site 027, Verona, New Jersey, United States
🇺🇸Investigative Site 011, West Palm Beach, Florida, United States
🇺🇸Investigative Site 024, Covington, Louisiana, United States
A Study Evaluating Safety, PK, and Efficacy of Tafasitamab and Parsaclisib in Participants With Relapsed/Refractory Non Hodgkin Lymphoma (R/R NHL) or Chronic Lymphocytic Leukemia (CLL)
- Conditions
- Chronic Lymphocytic LeukemiaNon Hodgkin Lymphoma
- Interventions
- First Posted Date
- 2021-03-22
- Last Posted Date
- 2024-11-18
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 54
- Registration Number
- NCT04809467
- Locations
- 🇺🇸
University of Southern California, Los Angeles, California, United States
🇺🇸Indiana Blood and Marrow Transplantation, Indianapolis, Indiana, United States
🇺🇸Ohio State University, Columbus, Ohio, United States
To Evaluate Efficacy and Safety of Parsaclisib Plus Either Rituximab or Obinutuzumab in R/R Follicular Lymphoma (FL) and Marginal Zone Lymphoma (MZL) (CITADEL-302)
- Conditions
- Follicular Lymphoma ( FL)Marginal Zone Lymphoma (MZL)
- Interventions
- First Posted Date
- 2021-03-15
- Last Posted Date
- 2022-07-18
- Lead Sponsor
- Incyte Corporation
- Registration Number
- NCT04796922
A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma or Marginal Zone Lymphoma.
- Conditions
- Follicular LymphomaMarginal Zone Lymphoma
- Interventions
- First Posted Date
- 2020-12-22
- Last Posted Date
- 2025-04-04
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 654
- Registration Number
- NCT04680052
- Locations
- 🇺🇸
John Muir Health Clinical Research Center, Concord, California, United States
🇺🇸Metro-Minnesota Community Oncology Reserch Consortium (Mmcorc), Saint Louis Park, Minnesota, United States
🇺🇸Hattiesburg Clinic Hematology, Hattiesburg, Mississippi, United States
A Rollover Study to Provide Continued Treatment for Participants Previously Enrolled in Studies of Itacitinib
- Conditions
- MyelofibrosisPostlung Transplant (Bronchiolitis Obliterans)Chronic Graft Versus Host Disease
- Interventions
- First Posted Date
- 2020-11-23
- Last Posted Date
- 2025-02-27
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 18
- Registration Number
- NCT04640025
- Locations
- 🇩🇪
University Hospital Mannheim, Mannheim, Germany
🇮🇹Azienda Policlinico Vittorio Emanuele, Catania, Italy
🇮🇹Aou San Giovanni Di Dio E Ruggi, Salerno, Italy
To Assess the Safety, Tolerability and Efficacy of Itacitinib Immediate Release Tablets in Participants With Primary or Secondary Myelofibrosis Who Have Received Prior Ruxolitinib and/or Fedratinib Monotherapy (LIMBER-213)
- Conditions
- Polycythemia VeraThrombocythemiaMyelofibrosis
- Interventions
- First Posted Date
- 2020-11-16
- Last Posted Date
- 2023-08-30
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 4
- Registration Number
- NCT04629508
- Locations
- 🇮🇹
Treviso Hospital, Treviso, Italy
🇺🇸Vanderbilt University, Nashville, Tennessee, United States
🇮🇹Istituto Di Ricovero E Cura A Carattere Scientifico (Irccs) Ospedale San Raffaele, Milan, Italy
Study of INCB086550 in Select Solid Tumors
- Conditions
- Non Small Cell Lung CancerRenal Cell CarcinomaHepatocellular CarcinomaMelanomaUrothelial Cancer
- Interventions
- First Posted Date
- 2020-11-16
- Last Posted Date
- 2025-03-13
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 16
- Registration Number
- NCT04629339
- Locations
- 🇺🇦
Medical Clinic Innovacia Llc, Vyshhorod, Ukraine
🇧🇬Shatod Dr. Marko - Varna Ltd, Varna, Bulgaria
🇭🇺Semmelweis Egyetem, Budapest, Hungary
An Umbrella Study to Determine the Safety and Efficacy of Various Monotherapy or Combination Therapies in Neoadjuvant Urothelial Carcinoma
- Conditions
- Urothelial Carcinoma
- Interventions
- First Posted Date
- 2020-10-14
- Last Posted Date
- 2025-03-10
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 30
- Registration Number
- NCT04586244
- Locations
- 🇮🇹
Istituto Tumori Giovanni Paolo Ii Irccs Ospedale Oncologico Bari, Bari, Italy
🇺🇸Oregon Health & Science University, Portland, Oregon, United States
🇫🇷Institut Gustave Roussy, Villejuif Cedex, France